UCSD Patient Gets First Cancer Treatment Made From Stem Cells
SAN DIEGO — A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells.
The patient, Derek Ruff, is being treated for stage four colon cancer, which recurred after a decade in remission. The disease continued to progress despite chemotherapy and radiation, said UCSD’s Dr. Sandip Patel, who treated Ruff.
Ruff is getting infusions of what are called “natural killer” or NK cells, made by San Diego’s Fate Therapeutics. Fate has worked closely with UCSD’s Dr. Dan Kaufman, an expert on these cells.
Ruff began getting multiple doses of NK cells in February. In early April, he said the immunotherapy hasn’t debilitated him like previous treatments.
“Before I got the first treatment, I was very apprehensive,” said Ruff, 52. “I had been through a lot of chemo, and chemo makes you feel really bad.”
It has yet to be determined if the NK cell treatment, called FT500, is working.
Fate is testing these NK cells in patients with advanced solid tumors, where a better-known cell therapy called chimeric antigen receptor, or CAR T cells, has shown limited benefit.
CAR T cells are genetically engineered to detect a specific molecular marker on the cancer cells. These cells have revolutionized cancer treatment, especially for blood cancers. Two approved treatments are available, Kymriah and Yescarta.
But the CAR T cells must be custom-made from the patient’s own cells, an expensive process that takes weeks. And they haven’t been extensively tested against solid tumors, such as Ruff’s.
Patel said he was particularly excited by the idea of treating solid tumors with NK cell therapies.
“Patients with solid tumors are the biggest population of patients that we see in aggregate, and are a major unmet need in terms of cellular immunotherapy,” Patel said.
FT500 is a first-of-kind product approved by the U.S. Food and Drug Administration for experimental use.
Unlike CAR T cells, which are custom-made from a patient’s own cells over a period of weeks, FT500 is produced in advance as an “off the shelf” treatment and doesn’t require immune matching. Due to economies of scale, “off-the-shelf” treatments are expected to cost less.
Fate starts with what are called induced pluripotent stem cells, or iPSCs. These are adult cells “reprogrammed” to resemble embryonic stem cells. These iPSCs are then matured into NK cells.
“This product is derived from a master bank of induced pluripotent stem cells that self-renew, and thus are able to continually make these NK cells,” Patel said. “If this works, patients can be treated en masse with these cells, given and administered like other drugs, but are living cellular products.”
©2019 The San Diego Union-Tribune
Visit The San Diego Union-Tribune at www.sandiegouniontribune.com
Distributed by Tribune Content Agency, LLC.
In The News
San Francisco could become the first city in the United States in which large commercial property owners use only renewable energy under a plan unveiled by Mayor London Breed earlier this week. She and city supervisors Vallie Brown and Ahsha Safaí are co-sponsoring legislation that would... Read More
A federal court ruling last week set a precedent for property rights to cannabis products in the quickly growing marijuana industry. U.S. District Judge William Martinez, an Obama appointee who presides in Colorado, ruled that cannabinoid formulations can be considered the unique handiwork of their developers... Read More
Both Social Security and Medicare are on unstable financial footing, and lawmakers need to act sooner rather than later to shore up America’s bedrock retirement programs and phase in needed changes, the trustees of both programs said in reports released Monday. Social Security is the government's... Read More
Hospitals and nursing homes in California and Illinois are testing a surprisingly simple strategy against the dangerous, antibiotic-resistant superbugs that kill thousands of people each year: washing patients with a special soap. The efforts — funded with roughly $8 million from the federal government’s Centers for... Read More
PHILADELPHIA — Sara Henya’s art is her music, and her instrument is the harp. She makes playing look easy, effortless. Her fingers move like cascading water: fluid, graceful, sure. But when her fingers are still, well, that’s a different story. Her brain barks orders her body... Read More
When Larry Anders moved into the Bay at Burlington nursing home in late 2017, he wasn’t supposed to be there long. At 77, the stoic Wisconsin machinist had just endured the death of his wife of 51 years and a grim new diagnosis: throat cancer, stage... Read More